vs
Side-by-side financial comparison of Baxter International (BAX) and Expedia Group (EXPE). Click either name above to swap in a different company.
Expedia Group is the larger business by last-quarter revenue ($3.5B vs $3.0B, roughly 1.2× Baxter International). Expedia Group runs the higher net margin — 5.8% vs -37.9%, a 43.7% gap on every dollar of revenue. On growth, Baxter International posted the faster year-over-year revenue change (458.0% vs 18.7%). Over the past eight quarters, Expedia Group's revenue compounded faster (-0.2% CAGR vs -9.0%).
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.
Expedia Inc. is an online travel agency owned by Expedia Group, based in Seattle. The website and mobile app can be used to book airline tickets, hotel reservations, car rentals, cruise ships, activities and vacation rentals. Expedia.com was launched on October 22, 1996 by Microsoft.
BAX vs EXPE — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.0B | $3.5B |
| Net Profit | $-1.1B | $205.0M |
| Gross Margin | 19.4% | — |
| Operating Margin | -24.5% | 11.8% |
| Net Margin | -37.9% | 5.8% |
| Revenue YoY | 458.0% | 18.7% |
| Net Profit YoY | -120.3% | 202.5% |
| EPS (diluted) | $-2.21 | $1.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $3.5B | ||
| Q4 25 | $3.0B | $3.5B | ||
| Q3 25 | $2.8B | $4.4B | ||
| Q2 25 | $2.8B | $3.8B | ||
| Q1 25 | $2.6B | $3.0B | ||
| Q4 24 | $533.0M | $3.2B | ||
| Q3 24 | $2.7B | $4.1B | ||
| Q2 24 | $3.8B | $3.6B |
| Q1 26 | — | $205.0M | ||
| Q4 25 | $-1.1B | $205.0M | ||
| Q3 25 | $-46.0M | $959.0M | ||
| Q2 25 | $91.0M | $330.0M | ||
| Q1 25 | $126.0M | $-200.0M | ||
| Q4 24 | $-512.0M | $299.0M | ||
| Q3 24 | $140.0M | $684.0M | ||
| Q2 24 | $-314.0M | $386.0M |
| Q1 26 | — | — | ||
| Q4 25 | 19.4% | — | ||
| Q3 25 | 33.5% | — | ||
| Q2 25 | 35.3% | — | ||
| Q1 25 | 32.8% | — | ||
| Q4 24 | 25.0% | — | ||
| Q3 24 | 38.3% | — | ||
| Q2 24 | 37.5% | — |
| Q1 26 | — | 11.8% | ||
| Q4 25 | -24.5% | 11.8% | ||
| Q3 25 | 6.1% | 23.5% | ||
| Q2 25 | 6.8% | 12.8% | ||
| Q1 25 | 2.2% | -2.3% | ||
| Q4 24 | -25.5% | 6.8% | ||
| Q3 24 | 5.7% | 18.8% | ||
| Q2 24 | -5.0% | 12.7% |
| Q1 26 | — | 5.8% | ||
| Q4 25 | -37.9% | 5.8% | ||
| Q3 25 | -1.6% | 21.7% | ||
| Q2 25 | 3.2% | 8.7% | ||
| Q1 25 | 4.8% | -6.7% | ||
| Q4 24 | -96.1% | 9.4% | ||
| Q3 24 | 5.2% | 16.8% | ||
| Q2 24 | -8.2% | 10.8% |
| Q1 26 | — | $1.56 | ||
| Q4 25 | $-2.21 | $1.56 | ||
| Q3 25 | $-0.09 | $7.33 | ||
| Q2 25 | $0.18 | $2.48 | ||
| Q1 25 | $0.25 | $-1.56 | ||
| Q4 24 | $-0.99 | $2.10 | ||
| Q3 24 | $0.27 | $5.04 | ||
| Q2 24 | $-0.62 | $2.80 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0B | $5.7B |
| Total DebtLower is stronger | $9.5B | $6.2B |
| Stockholders' EquityBook value | $6.1B | $1.3B |
| Total Assets | $20.1B | $24.5B |
| Debt / EquityLower = less leverage | 1.55× | 4.80× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.7B | ||
| Q4 25 | $2.0B | $5.7B | ||
| Q3 25 | $1.7B | $6.2B | ||
| Q2 25 | $1.7B | $6.7B | ||
| Q1 25 | $2.3B | $6.1B | ||
| Q4 24 | $1.8B | $4.5B | ||
| Q3 24 | $1.4B | $4.9B | ||
| Q2 24 | $2.1B | $6.3B |
| Q1 26 | — | $6.2B | ||
| Q4 25 | $9.5B | $6.2B | ||
| Q3 25 | — | $6.2B | ||
| Q2 25 | — | $6.2B | ||
| Q1 25 | — | $6.2B | ||
| Q4 24 | $10.4B | $6.3B | ||
| Q3 24 | $10.4B | $6.3B | ||
| Q2 24 | $10.4B | $6.3B |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $6.1B | $1.3B | ||
| Q3 25 | $7.2B | $1.3B | ||
| Q2 25 | $7.3B | $836.0M | ||
| Q1 25 | $7.1B | $1.1B | ||
| Q4 24 | $7.0B | $1.6B | ||
| Q3 24 | $7.9B | $1.3B | ||
| Q2 24 | $7.6B | $889.0M |
| Q1 26 | — | $24.5B | ||
| Q4 25 | $20.1B | $24.5B | ||
| Q3 25 | $21.1B | $25.1B | ||
| Q2 25 | $21.0B | $27.0B | ||
| Q1 25 | $21.3B | $26.1B | ||
| Q4 24 | $25.8B | $22.4B | ||
| Q3 24 | $26.7B | $23.4B | ||
| Q2 24 | $26.3B | $25.9B |
| Q1 26 | — | 4.80× | ||
| Q4 25 | 1.55× | 4.80× | ||
| Q3 25 | — | 4.65× | ||
| Q2 25 | — | 7.43× | ||
| Q1 25 | — | 5.79× | ||
| Q4 24 | 1.49× | 4.02× | ||
| Q3 24 | 1.33× | 4.74× | ||
| Q2 24 | 1.37× | 7.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $584.0M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $584.0M | $304.0M | ||
| Q3 25 | $237.0M | $-497.0M | ||
| Q2 25 | $217.0M | $1.1B | ||
| Q1 25 | $-193.0M | $3.0B | ||
| Q4 24 | $488.0M | $198.0M | ||
| Q3 24 | $253.0M | $-1.5B | ||
| Q2 24 | $115.0M | $1.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | $119.0M | ||
| Q3 25 | — | $-686.0M | ||
| Q2 25 | — | $921.0M | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $7.0M | ||
| Q3 24 | — | $-1.7B | ||
| Q2 24 | — | $1.3B |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.4% | ||
| Q3 25 | — | -15.5% | ||
| Q2 25 | — | 24.3% | ||
| Q1 25 | — | 92.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | -41.6% | ||
| Q2 24 | — | 36.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.2% | ||
| Q3 25 | — | 4.3% | ||
| Q2 25 | — | 5.3% | ||
| Q1 25 | — | 6.6% | ||
| Q4 24 | — | 6.0% | ||
| Q3 24 | — | 4.8% | ||
| Q2 24 | — | 5.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.48× | ||
| Q3 25 | — | -0.52× | ||
| Q2 25 | 2.38× | 3.40× | ||
| Q1 25 | -1.53× | — | ||
| Q4 24 | — | 0.66× | ||
| Q3 24 | 1.81× | -2.18× | ||
| Q2 24 | — | 3.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BAX
| Other | $1.5B | 51% |
| Infusion Therapies And Technologies | $543.0M | 18% |
| Pharmaceutical Compounding | $316.0M | 11% |
| Front Line Care | $219.0M | 7% |
| Injectables And Anesthesia | $190.0M | 6% |
| Advanced Surgery | $177.0M | 6% |
EXPE
Segment breakdown not available.
